CEO research orientation, organizational context, and innovation in the pharmaceutical industry

被引：21
|
作者：
van de Wal, Nino [1 ]
Boone, Christophe [1 ]
Gilsing, Victor [1 ,2 ]
Walrave, Bob [3 ]
机构：
[1] Univ Antwerp, Dept Management, ACED, Antwerp, Belgium
[2] Vrije Univ Amsterdam, Sch Business & Econ, Amsterdam, Netherlands
[3] Eindhoven Univ Technol, Sch Ind Engn, Eindhoven, Netherlands
来源：
R & D MANAGEMENT | 2020年 / 50卷 / 02期
关键词：
TOP MANAGEMENT TEAM; UPPER ECHELONS; FIRM; PERFORMANCE; LEADERSHIP; CULTURE; DETERMINANTS; EXPLORATION; PERSPECTIVE; EVOLUTION;
D O I：
10.1111/radm.12394
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
This study develops and tests a comprehensive framework that explains what, when, and how CEO characteristics influence firms' innovation outcomes in R&D-intensive industries. Empirical evidence from 109 CEOs from 87 U.S.-based pharmaceutical firms over the period 2001-2013 reveals that research-oriented CEOs - those with ability and motivation for science and technology - increase their firms' innovation outcomes. The results indicate that the CEO-innovation relationship strongly depends on the extent of CEOs' managerial discretion, which is shaped by the organizational context. We contribute to a more comprehensive understanding of the role of CEOs in firms ' innovation performance differentials.
引用
收藏
页码：239 / 254
页数：16
相关论文
共 50 条
12345